Tg Immunopharma Has Announced That The Fda Has Approved The Clinical Investigation Of Tgi-6, For The Development Of Breakthrough Bispecific Antibody.Tgi-6 Is A Novel Antibody Developed To Target Both Tumour-Associated Antigens (Taa) And Cd3 Molecules. This Dual Targeting Mechanism Is Designed To Enhance Anti-Tumour Responses. By Binding To Taas, Which Are Specific To Cancer Cells, Tgi-6 Can Directly Recognise And Attack Tumour Cells.Tgi-6, A Novel Therapeutic Agent, Has Been Specifically Engineered To Uphold Potent Cytotoxic Effects While Mitigating The Potential For Cytokine Release Syndrome (Crs). Tgi-6 Has Demonstrated Superior Antitumor Activity And Safety In Preclinical Studies.Tgi-6 Taa Is Highly Expressed In Several Solid Tumours, Including Colon Cancer, Breast Cancer, Hepatocellular Carcinoma, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer And Many Others. This Makes Tgi-6 A Promising Candidate For The Treatment Of Many Solid Tumours.Preclinical Investigations Have Showcased The Remarkable Potential Of Tgi-6, As It Achieved Complete Regression Of Tumours In Animal Models Of Colourectal Cancer Following A Single Administration. Tgi-6 Is Specifically Designed To Uphold Potent Cytotoxic Activity While Mitigating The Potential For Cytokine Release Syndrome (Crs).
